已经开发了一种高效的培美曲塞二钠合成方法,该方法以4-碘苯甲酸甲酯和3-丁烯-1-醇为原料,经过六个步骤。与报道的合成路线相比,开发的过程避免了一些繁琐的后处理程序和不友好的试剂。另外,分离出该方法中产生的两种杂质,并通过1 H NMR,13 C NMR和HRMS进行表征。还讨论了这两种杂质的机理,并且可以通过适当的后处理程序轻松去除杂质。培美曲塞二钠的总产率从12.8%(文献)提高到34.9%。因此,这种经济高效,环保且高产的工艺更适合于培美曲塞二钠的大规模生产。
Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
申请人:Cheng Lin
公开号:US10736969B2
公开(公告)日:2020-08-11
Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
[EN] PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE PÉMÉTREXED ET DU SEL DE LYSINE DE CELUI-CI
申请人:BERLIN CHEMIE AG
公开号:WO2014024164A1
公开(公告)日:2014-02-13
The present invention refers to a process for the synthesis of pemetrexed and salts thereof, in particular to a lysine salt thereof, to said salt as such and to pharmaceutical compositions that comprise the same. Furthermore, the present disclosure also relates to a crystalline form of the synthesis intermediate pemetrexed diethyl ether and a crystalline form of the pemetrexed lysine salt.
[EN] ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES<br/>[FR] MÉDICAMENTS LIEURS D'ANTIFOLATE ET CONJUGUÉS ANTICORPS-MÉDICAMENT
申请人:BYONDIS BV
公开号:WO2022008419A1
公开(公告)日:2022-01-13
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.
Synthesis and antiviral study of novel 4-(2-(6-amino-4-oxo-4,5-dihydro-1H-pyrrolo[2,3-d]pyrimidin-3-yl)ethyl)benzamide derivatives
作者:Selvakumar Balaraman、Nagaraj Nayak、Madhuri Subbiah、Kuppanagounder P. Elango
DOI:10.1007/s00044-018-2256-z
日期:2018.12
chemically known as N-4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-l-glutamic acid, with primary, secondary, and aryl amines in high yields using diethylphosphorocyanidate (DEPC) as a peptide coupling agent. All the synthesized compounds are characterized by 1H and 13C NMR, LCMS, and FT-IR spectral techniques. All the synthesized novel non-glutamate 4-(2-(6-amino-4-oxo-4,
通过绝对替代培美曲塞药物的谷氨酸部分(化学名称为N- 4- [2-(2-(2-氨基-4-氧代-4,7-二氢])),合成了一系列十个新化合物(7a–j) -3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酰基} -1-谷氨酸,具有伯胺,仲胺和芳基胺,使用二乙基磷腈基氰酸酯(DEPC)作为肽偶联剂可以高收率。所有合成的化合物的特征在于1 H和1313 C NMR,LCMS和FT-IR光谱技术。所有合成的新型非谷氨酸4-(2-(6-氨基-4-氧代-4,5-二氢-1H-吡咯并[2,3-d]嘧啶-3-基)乙基)苯甲酰胺衍生物均显示4-其抗病毒活性比其结构相似的商业药物Pemetrexed抗禽副粘病毒新城疫病毒高7倍。其中,具有使用五元杂芳基胺(7i和7j)合成的具有羧酰胺的化合物表现出最高的抗病毒活性。
Determination of the Source of the <i>N</i>-Methyl Impurity in the Synthesis of Pemetrexed Disodium Heptahydrate
作者:Douglas P. Kjell、Dallas W. Hallberg、J. Michael Kalbfleisch、Cynthia K. McCurry、Michael J. Semo、Edward M. Sheldon、Jeremy T. Spitler、Ming Wang
DOI:10.1021/op0498013
日期:2005.11.1
The synthesis of PemetrexedDisodium Heptahydrate has consistently resulted in a very low level (ca. 0.02%) unknown impurity. To ensure long-term control, the identity and source of the impurity were desired. Isolation and characterization identified the impurity as the N-methyl derivative. The source was identified as the methyl groups on the peptide coupling agent, 2,6-Dimethoxy-1,3,5-triazine (CDMT)